An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the le
Ana-Maria Stanciuc
Original Source
The Next Web
https://thenextweb.com/news/kupando-series-a-kup101-phase-1b-innate-immunity
An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the learned, antibody-generating machinery that checkpoint inhibitors like pembrolizumab […]
This story continues at The Next Web
Found this useful? Share it!
Read the Full Story
Continue reading on The Next Web
Related Stories
These AI notetaking devices can help you record and transcribe your meetings
25 minutes ago
BBLeap raises €5M to bring plant-level precision spraying to arable farms globally
32 minutes ago
Apollo.io acquires Pocus as it pushes to build an AI-native operating system for sales teams
44 minutes ago
Perplexity has launched Perplexity Health
about 2 hours ago